Compare HIMX & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMX | IRON |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2006 | 2020 |
| Metric | HIMX | IRON |
|---|---|---|
| Price | $11.95 | $57.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $30.20 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 1.0M | 577.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.09 | N/A |
| Revenue Next Year | $29.62 | N/A |
| P/E Ratio | $14.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.85 | $40.00 |
| 52 Week High | $25.09 | $99.50 |
| Indicator | HIMX | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 33.06 | 27.40 |
| Support Level | $11.39 | $40.00 |
| Resistance Level | $12.00 | $82.89 |
| Average True Range (ATR) | 0.52 | 2.59 |
| MACD | -0.28 | -0.39 |
| Stochastic Oscillator | 16.38 | 16.28 |
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.